Medically reviewed by Archana Sharma, DO Key Takeaways Active surveillance, or watchful waiting, is often recommended for ...

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, ...

Chronic lymphocytic leukemia (CLL) is often a chronic disease; many patients receive more than one treatment over the course ...

Ibrutinib normalizes RBC aggregation in CLL, potentially reducing thrombotic risks by mitigating blood flow complications. Obinutuzumab/venetoclax combination does ...

Researchers at the University of Eastern Finland and their international collaborators have identified key developmental and molecular differences between the two main subtypes of chronic lymphocytic ...

In the age of targeted therapy, what’s the best long-term strategy to treat chronic lymphocytic leukemia (CLL), the most common leukemia in Western countries? Should treatment be continuous to achieve ...

About 10 percent of patients with chronic lymphocytic leukemia (CLL) discontinued therapy with the Bruton tyrosine kinase (BTK) inhibitor drug ibrutinib because of disease progression during clinical ...

Developments in chronic lymphocytic leukemia (CLL) this year included the first CAR T-cell therapy approval for the chronic blood cancer, potential treatments for Richter transformation, and ...

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapy BRUKINSA plus ...

Prompt recognition of autoimmune disease symptoms can help patients with chronic lymphocytic leukemia receive proper rheumatologic care. Immune dysregulation associated with chronic lymphocytic ...

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally ...